Clinical-Stage AI Platform  
Advancing Therapies for Rare and Inflammatory Diseases

Inflammatory diseases like Acute Respiratory Distress Syndrome (ARDS), Cystic Fibrosis, Pneumonia, Bronchiolitis Obliterans, RSV, IPF, COPD, Asthma, Sepsis, Rheumatoid Arthritis, Multiple Sclerosis, Inflammatory Bowel Disease and many other devastating diseases share a common p38 MAPK stress- and cytokine-activated kinases pathway which contributes to pathogenesis of these diseases.

These diseases cause suffering to millions of patients and families and cost society billions of dollars.

Our focus is on those inflammatory diseases which currently do not have effective treatment.

GEn1E Highlights

GEn1E’s team, led by Dr. Ritu Lal, has decades of experience working on drug development including  first-generation p38 drugs and platform technologies

Key building blocks of GEn1E Platform


Curated database includes GEn1E generated proprietary data for our drugs as well curated data for inflammatory and rare diseases


Each inflammatory disease has its own unique signature as expressed with multiple biomarkers. The platform matches our drug’s unique signature with the inflammatory disease signature to select the best match of our drug for the disease

Machine Learning Engine

We utilize a continuous feedback loop across the entire process from discovery to clinical studies.
Neural Networks, Gradient Boosting Methods and Hidden Markov Models are used to accelerate drug development

GEn1E chose ARDS as our first-to-market indication

ARDS is an acute diffuse, inflammatory lung injury, leading to increased pulmonary vascular permeability, increased lung weight, and loss of aerated lung tissue.
In ARDS, fluid leaks into lungs making it difficult to absorb oxygen and the patient cannot breathe

Learn more about ARDS

Team has strong domain expertise in drug development and p38 kinase inhibitors

The founding CEO, Dr. Ritu Lal, has taken drugs from discovery through FDA approval 3 times. She has worked on previous generation p38 drugs and has formed a world-class team, which also includes stellar Advisors and many of the world’s top ARDS experts

Strong domain expertise in p38, drug development and AI platform development 
Team includes world’s leading ARDS experts
Backed by stellar Investors, Advisors and Accelerators

Get in touch with us!

We are based in Palo Alto with a lab in Mountain View.

We look forward to joining forces with you to cure rare and inflammatory diseases, fast!

Contact Us
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.